Cargando…
Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom
INTRODUCTION: The glucagon-like peptide-1 (GLP-1) receptor agonist class has grown in the last decade, with several agents available in the UK. However there is currently a paucity of evidence regarding the relative cost-effectiveness of liraglutide 1.2 mg versus other daily administered GLP-1 recep...
Autores principales: | Hunt, Barnaby, Ye, Qing, Valentine, William J., Ashley, Donna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306118/ https://www.ncbi.nlm.nih.gov/pubmed/28058656 http://dx.doi.org/10.1007/s13300-016-0219-2 |
Ejemplares similares
-
Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain
por: Mezquita-Raya, Pedro, et al.
Publicado: (2017) -
Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016) -
Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States
por: Langer, Jakob, et al.
Publicado: (2013) -
IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting
por: Hunt, Barnaby, et al.
Publicado: (2017) -
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)